Castle Biosciences, Inc.
CSTL
$21.98
$0.843.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 332.07M | 311.88M | 287.59M | 250.73M | 219.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 332.07M | 311.88M | 287.59M | 250.73M | 219.79M |
| Cost of Revenue | 60.21M | 56.45M | 52.16M | 48.69M | 44.98M |
| Gross Profit | 271.86M | 255.43M | 235.43M | 202.03M | 174.81M |
| SG&A Expenses | 200.05M | 194.17M | 188.29M | 181.89M | 180.15M |
| Depreciation & Amortization | 11.11M | 9.04M | 9.04M | 9.04M | 9.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 323.40M | 312.92M | 303.35M | 292.65M | 287.77M |
| Operating Income | 8.67M | -1.04M | -15.76M | -41.93M | -67.98M |
| Income Before Tax | 21.56M | 11.14M | -4.02M | -30.66M | -57.37M |
| Income Tax Expenses | 3.32M | 5.06M | -918.00K | 132.00K | 101.00K |
| Earnings from Continuing Operations | 18.25 | 6.08 | -3.10 | -30.80 | -57.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.25M | 6.08M | -3.10M | -30.80M | -57.47M |
| EBIT | 8.67M | -1.04M | -15.76M | -41.93M | -67.98M |
| EBITDA | 24.67M | 12.42M | -2.67M | -29.15M | -55.65M |
| EPS Basic | 0.65 | 0.22 | -0.12 | -1.15 | -2.15 |
| Normalized Basic EPS | 0.47 | 0.25 | -0.10 | -0.71 | -1.34 |
| EPS Diluted | 0.61 | 0.20 | -0.14 | -1.15 | -2.16 |
| Normalized Diluted EPS | 0.44 | 0.23 | -0.10 | -0.71 | -1.34 |
| Average Basic Shares Outstanding | 111.10M | 110.00M | 109.00M | 108.08M | 107.20M |
| Average Diluted Shares Outstanding | 115.82M | 112.65M | 110.09M | 108.08M | 107.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |